@genetic-counselor
Genetic Counselor
Forum Replies Created
-
Posts
-
Immune checkpoint inhibitors (ICIs) particularly anti-PD-1 agents like pembrolizumab and cemiplimab have shown notably strong responses in Xeroderma Pigmentosum-associated cancers. The underlying rationale is that NER deficiency causes tumors to accumulate an extremely high mutational burden (from unrepaired UV damage), and tumors with high mutation loads tend to respond better to checkpoint inhibition because they generate more neoantigens for the immune system to target.
A retrospective multicenter study of 22 XP patients with metastatic or unresectable cancers treated with ICIs found that all 22 patients (100%) showed tumor regression or remission in response to treatment. Encouragingly, the frequency and type of adverse events in these Xeroderma Pigmentosum patients were comparable to those seen in ICI-treated patients in the general population, suggesting the treatment is not disproportionately riskier for Xeroderma Pigmentosum patients despite their underlying DNA repair defect.
For Xeroderma Pigmentosum patients who develop advanced squamous cell carcinoma or melanoma unsuitable for surgery/radiation, ICIs represent a genuinely effective option, rather than just a palliative approach.
Reference:
Fernandez ER, Tamura D, Khan SG, et al. Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers. Frontiers in Oncology, 2023. DOI: 10.3389/fonc.2023.1282823. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634243/Protection centers on near-total UV avoidance and early cancer surveillance:
*UV avoidance: Strict indoor lifestyle during daylight hours; window films that block UV-A/UV-B on homes, cars, and schools; UV-protective clothing (UPF 50+), wide-brimmed hats, and UV-blocking face shields/visors when outdoors is unavoidable.
*Broad-spectrum sunscreen: SPF 50+ with both UVA and UVB coverage, reapplied every 2 hours during any outdoor exposure.
*Eye protection: Wraparound UV-blocking sunglasses, as xeroderma pigmentosum (XP) also causes corneal and conjunctival damage, photophobia, and ocular tumors.
*Vitamin D monitoring: Since sun avoidance is near-total, patients need periodic vitamin D level checks and supplementation.
*Skin surveillance: Dermatologic exams every 3–6 months for early detection of basal cell carcinoma, squamous cell carcinoma (SCC), and melanoma, which can appear by age 10 in untreated patients.
*Neurological monitoring: Annual neurology and audiology assessment in XP subtypes with neurodegeneration risk (notably XP-A, XP-D).
*Genetic counseling: For parents planning future pregnancies, given the autosomal recessive inheritance and 25% recurrence risk per pregnancy.With rigorous photoprotection instituted early, studies show skin cancer incidence in XP patients can be reduced substantially compared to those without strict UV avoidance, early diagnosis and behavior change are the single biggest determinants of outcome.
Xeroderma pigmentosa (XP) is a rare autosomal recessive disorder caused by mutations in one of the nucleotide excision repair (NER) genes (XPA–XPG) or in the POLH gene (XP variant type). These genes normally repair DNA damage caused by ultraviolet (UV) radiation. When this repair pathway fails, UV-induced DNA damage accumulates in skin cells rather than being corrected, leading to severe photosensitivity, early freckling, premature skin aging, and a dramatically elevated risk of skin cancers from a very young age. In about a third of patients, progressive neurodegeneration also occurs due to unrepaired DNA damage in neurons.
In simple words, It happens when the body’s natural “DNA repair system” doesn’t work properly. Normally, when sunlight (UV rays) damages our skin cells, our body fixes that damage automatically. In XP, this repair process doesn’t happen the way it should — so damage builds up over time.
This is why people with XP get severe sunburns very easily, develop freckling and skin changes at a young age, and have a much higher chance of developing skin cancer early in life. In some cases, it can also affect the nervous system over time.
Yes. Genetic testing can help identify chromosomal or gene-related causes behind infertility or repeated pregnancy loss in some cases, which can guide further treatment or family planning decisions.
This can be worth discussing with a genetic counselor, especially for communities with a known higher carrier rate for certain conditions. Pre-marital or pre-conception carrier screening can help couples understand their risk and plan ahead.
No. A positive result means an increased risk compared to the general population, not a certainty. Many people with a cancer-related gene change never develop cancer, especially with appropriate monitoring and preventive care.
Genetic testing can identify certain gene changes linked to a higher risk of developmental conditions in some cases, but autism and learning disabilities usually involve a mix of genetic and non-genetic factors. Testing can sometimes provide a partial answer or rule out specific known causes, but it does not give a definite prediction in most cases.
Yes, for many conditions. While the underlying gene change doesn’t change, factors like diet, environment, and medical care can influence how severely a condition presents or how early it appears.
Your actual chromosomes don’t change over time (with rare exceptions like certain cancers, where testing is done on tumor cells specifically, not blood). So for constitutional/inherited testing like a karyotype result is a one-time, stable answer once it’s finalized. What can change between draws is the clarity or resolution of the result, for the technical reasons discussed above (culture quality, staining, imaging) which is different from the underlying biology changing. If a lab asks for a repeat sample, it’s almost always to get a better technical read, not because your chromosomes themselves are in flux.
Being a carrier of a chromosomal change (like a balanced translocation or a small deletion) usually means the rearranged material is present in your cells but doesn’t cause health problems for you personally, many carriers are completely healthy and only discover their status after having an affected child.
The relevance is mainly for reproductive planning: carriers can have an increased chance of passing on an unbalanced version of the change to future pregnancies, which is why genetic counseling matters here. Your geneticist can walk you through your specific numbers and options, including preimplantation or prenatal testing for future pregnancies, once your own results are finalized. This is exactly the kind of question worth bringing directly to your genetics team, since the implications depend on the precise type and location of the change.These three tests look at your chromosomes at different levels of detail, and geneticists often use them together rather than picking just one:
*Karyotype- a whole-genome overview. It shows the number and general structure of all 46 chromosomes and can catch large-scale changes (extra/missing chromosomes, big deletions or rearrangements), but it can’t see very small changes.
*Fluorescence In Situ Hybridization- a targeted test. A fluorescent probe is designed to bind to one specific region of interest, giving a fast, precise yes/no answer about that particular spot, but it only checks the region(s) you test for, not the whole genome. The results turn around time is faster compared to karyotyping.
*Chromosomal Microarray (CMA)- a genome-wide scan for small gains or losses of genetic material, at a resolution far beyond standard karyotyping, though it generally can’t detect balanced rearrangements (where material is rearranged but nothing is gained or lost).A standard karyotype typically takes 1–3 weeks, which is longer than many genetic blood tests because it isn’t a direct DNA readout – the lab has to actually grow your cells in culture first. Turnaround time depends on how quickly the cells divide (this varies person to person), how many rounds of culturing and staining are needed to get a clean, analyzable spread, and whether the finding is straightforward or needs extra review. A “delay” usually means the lab is being thorough, not that something is necessarily wrong.
A standard karyotype isn’t a direct photograph of your DNA – it’s produced by growing your blood cells in a lab culture, chemically arresting them right when the chromosomes are condensed (metaphase), staining them with a dye, and then photographing and arranging them under a microscope. Every step introduces variability:
*How well the cells divided in culture
*How tightly condensed the chromosomes were at the moment they were captured
*The quality/technique of the staining and banding
*Lab-to-lab and even sample-to-sample handling differencesBecause of this, it’s completely normal for one person’s chromosome spread to come out sharper than another’s – even from the same lab, same day. This is a technical limitation of the method, not a biological difference in your chromosomes.
Standard karyotyping relies on “banding patterns” – light and dark stripes along each chromosome that help identify structure and detect large changes. Near the telomeres (chromosome ends), these bands compress and become harder to distinguish. Small terminal deletions or rearrangements are notoriously easy to miss or misjudge on a standard karyotype precisely because of this end-of-chromosome resolution limit. This is likely exactly what your geneticist meant by “not as easy to see.”
Why they need another sample from your daughter,
When results are ambiguous, especially near a terminal region, labs typically escalate to a repeated karyotyping or higher-resolution, more targeted test:
*FISH (Fluorescence In Situ Hybridization) – uses a fluorescent probe designed to bind to the specific region of chromosome 13 that’s deleted in your daughter. This gives a much sharper, targeted answer than standard banding.
*Chromosomal Microarray (CMA) – scans for tiny gains or losses of genetic material at a resolution standard karyotyping simply can’t achieve.For either of these to give a reliable, comparable answer, the lab often needs a fresh, matched sample – partly because probes/reagents work best on freshly cultured cells, and partly so they can run your daughter’s sample using the same targeted method as yours, allowing a direct, apples-to-apples comparison of the exact region in question.
The difference you were told about (a “less easy to see” result vs. a “clear” one) reflects the technical limits of standard karyotyping, particularly around chromosome ends — not a difference in the health or normalcy of your chromosomes. The follow-up sample from your daughter is about using a more precise, targeted method to nail down whether the same deletion is present in you, using an approach that gives a clean side-by-side comparison.
Whole exome sequencing looks at the protein-coding parts of all your genes at once, while whole genome sequencing looks at your entire genetic code. These broader tests are usually recommended when a specific gene is not suspected, or when more targeted tests have not found an answer, especially in complex or undiagnosed conditions.
